Company intelligence / Profile preview

Athenex

Buffalo, New York, United Stateslinkedin.com ↗

Ownership: Public · ATNX
Employees: ~599
Development stage: Commercial

Overview

Athenex has multiple products in development and on the market, including sterile high-potency oncology drugs. The company completed construction of a manufacturing facility in Dunkirk, New York in 2020, with operations expected to begin in Q2 2021.

Therapeutic areas: OncologyImmunology
Modalities: Small moleculessterile high-potency oncology drugs
Industry: Biotech

Drug pipeline

9 assets

tirbanibulin

Approved

8 more assets in the full pipeline.

Request access →

Partnerships

State University of New York Polytechnic Institute (SUNY Polytechnic Institute)Hanmi Pharmaceuticals

Financials

Market cap: $2.3M
Total revenue: $25.1M
Enterprise value: $8M

Beyond the preview

Go deeper on Athenex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Athenex.

Explore the full profile